Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (CYTK +3.00%), exercised 15,000 options […]
On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (CYTK +3.00%), exercised 15,000 options […]
This article was written by Follow Harrison is a financial analyst who has been writing on Seeking Alpha since 2018